Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

Leukemia, Myeloid, Acute Clinical Trial

Official title:

To Evaluate Safety and Efficiency of AZA Combined With Chidamide as Maintenance Therapy in High-risk Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation：A Multicenter, Single-arm Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05270200
• Other study ID #: AZA+Chidamide
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: February 1, 2022
• Est. completion date: July 1, 2024

Study information

• Verified date: December 2021
• Source: Zhujiang Hospital
• Contact: Rui Huang, Doctor
• Phone: +8615918528317
• Email: Rachelchn[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical research study is to learn if azacitidine combined with Chidamide will help to control the disease in patients with high-risk AML after an allogeneic stem cell transplant. The safety of this combination will also be studied.

Description:

The Study Drug: Azacitidine is designed to block certain genes in cancer cells whose job is to stop the function of the tumor-fighting genes. By blocking the "bad" genes, the tumor-fighting genes may be able to work better. Chidamide exhibits potent inhibitory effect on cell viability of MDS and AML cells, and the possible mechanism may lie in the downregulation of JAK2/STAT3 signaling through SOCS3 upregulation. Study Group： If you are found to be eligible to take part in this study,you will receive azacitidine and chidamide. Study Drug Administration: You will recieve six courses of azacitidine through a needle under your skin on Days 1-5.Each course is 28 days long.At the same time you will recieve oral chidamide per day for no more than 2 years. The treatment will start after 60 days post-transplantation and your neutrophil count is of 1.5 × 10⁹ cells per L or higher and non-transfused platelets is of 80 × 10⁹ per L or higher. The treatment would stop if neutrophil count is less than 0.5 × 10⁹ cells per L or platelets is less than 20 × 10⁹ per L.And it would also stop when grade 3/4 non-hematological adverse events happened. Study Visit: You may come back for study visits every month in a year when the treatment start. Blood and urine will be drawn for routine tests every month. At 1,2,3,4,5,6,9 and 12 months,You will have a bone marrow aspiration to check the status of the disease. You will have a electrocardiiogram test every 3 months to check the heart function. Length of Study: You will be on study treatment for up to 1 year.You will be taken off study early if you experience intolerable side effects or the disease gets worse. End-of-Treatment Visit: If you complete the planned treatment with azacitidine and chidamide, you will have an end-of-treatment visit: Blood and urine will be drawn for routine tests. You will have a bone marrow aspiration to check the status of the disease. You will have a electrocardiiogram test every 3 months to check the heart function. This is an investigational study. Azacitidine and chidamide are FDA approved and are commercially available for the treatment of acute leukemia.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: July 1, 2024
• Est. primary completion date: February 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• 1.Age 18 to 60 years old,both male and female
• 2.Be able to understand and sign informed consent
• 3.Patients with a diagnosis of AML not M3 according to the 2016 World Health Organization (WHO) Acute Myeloid Leukemia Classification and Diagnostic
• 4.Patients have AML with poor genetic abnormalities,primary refractory AML,relapsed AML or secondary AML
• 5.Patients with an ECOG performance status 0,1,2 or 3
• 6.Expected survival time = 3 months
• 7.Non-hematological toxicity related to transplantation does not exceed Grade 2
• 8.Laboratory indicators meet the following standards:

1. 7 days before the first day of the first course of treatment, bilirubin, ALT and AST were all less than 3 times the upper limit of normal.

2. Measure twice within 7 days before the first day of the first course of treatment, at least 2 days apart, the neutrophil count are greater than 1.5×10/L and without G-CSF treatment.

3. Measure twice within 7 days before the first day of the first course of treatment, at least 2 days apart, platelet count greater than 80×10/L and without platelet transfusion.

4. Serum creatinine clearance rate is greater than 30ml/min.

Exclusion Criteria:

• 1.Uncontrollable active infection
• 2.Patients with active hepatitis B or C or HIV infection before enrollment
• 3.Have a grade III-IV graft-versus-host disease

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Drug:
• Azacitidine
Patients will recieve six courses of azacitidine 100mg through a needle under skin on Days 1-5.Each course is 28 days long.
• Chidamide
Patients will recieve oral chidamide 5mg per day for no more than 2 years.

Locations

Country	Name	City	State
China	Nanfang Hospital of Southern Medical University	Guanzhou	Guandong

Sponsors (1)

Lead Sponsor	Collaborator
Zhujiang Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Paticipants With Adverse Events as a Measure of Safety	Safety were measured with respect to: Safety measurements; Incidence of adverse events	From the day of stem cell transplantation to one year after stem cell transplantation
Primary	One year cumulative incidence of relapse	Leukemia relapse base on morphoogy criterion	From the day of stem cell transplantation to one year after stem cell transplantation
Secondary	Relapes-free Survival(RFS)	The time that a participant survives without relapes of the disease	From the day of stem cell transplantation to one year after stem cell transplantation
Secondary	Overall survival(OS)	The time that a participant survives without death	From the day of stem cell transplantation to one year after stem cell transplantation
Secondary	The cumulative Incidence rate of GVHD	acute GVHD and chronic GVHD diagnosis based on MIH criterion	From the day of stem cell transplantation to one year after stem cell transplantation